Kadmon Holdings, Inc.(NASDAQ : KDMN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||2.23%||8.71||0.7%||$608.86m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.20%||651.88||2.7%||$494.43m|
|GILD||Gilead Sciences, Inc.||0.39%||71.61||1.0%||$434.34m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.64%||188.30||1.9%||$241.59m|
|ISEE||IVERIC bio, Inc.||1.59%||16.62||0.0%||$194.78m|
|LIFE||aTyr Pharma, Inc.||0.49%||10.31||3.2%||$144.19m|
|EXAS||EXACT Sciences Corp.||5.22%||108.15||18.1%||$135.69m|
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.